Taylor AA - Search Results

1

Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.

Pool JL, Taylor AA, Nelson EB. Pool JL, et al. Among authors: taylor aa. Am J Med. 1989 Aug 16;87(2A):57S-61S. doi: 10.1016/0002-9343(89)90115-0. Am J Med. 1989. PMID: 2569825 Review.

2

Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.

Pool JL, Lenz ML, Taylor AA. Pool JL, et al. Among authors: taylor aa. J Hum Hypertens. 1990 Oct;4 Suppl 3:23-33. J Hum Hypertens. 1990. PMID: 1979819

3

Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients.

Pool JL, Nelson EB, Taylor AA. Pool JL, et al. Among authors: taylor aa. Am J Med. 1988 Sep 23;85(3B):19-24. doi: 10.1016/0002-9343(88)90345-2. Am J Med. 1988. PMID: 2844082 Review.

4

Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.

Lenz ML, Pool JL, Laddu AR, Varghese A, Johnston W, Taylor AA. Lenz ML, et al. Among authors: taylor aa. Am J Hypertens. 1995 Feb;8(2):133-45. doi: 10.1016/0895-7061(94)00162-5. Am J Hypertens. 1995. PMID: 7755941 Clinical Trial.

5

Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.

Pool JL, Nelson EB, Taylor AA, Mitchell JR. Pool JL, et al. Among authors: taylor aa. Br J Clin Pract Suppl. 1987 Dec;54:9-14. Br J Clin Pract Suppl. 1987. PMID: 2905162 Clinical Trial. No abstract available.

6

Spectrum of dysautonomia in mitral valvular prolapse.

Taylor AA, Davies AO, Mares A, Raschko J, Pool JL, Nelson EB, Mitchell JR. Taylor AA, et al. Am J Med. 1989 Mar;86(3):267-74. doi: 10.1016/0002-9343(89)90294-5. Am J Med. 1989. PMID: 2919608

7

Mitral valve prolapse with symptoms of beta-adrenergic hypersensitivity. Beta 2-adrenergic receptor supercoupling with desensitization on isoproterenol exposure.

Davies AO, Mares A, Pool JL, Taylor AA. Davies AO, et al. Among authors: taylor aa. Am J Med. 1987 Feb;82(2):193-201. doi: 10.1016/0002-9343(87)90055-6. Am J Med. 1987. PMID: 3028141

8

Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study.

Taylor AA, Mangoo-Karim R, Ballard KD, Luther RR, Pool JL. Taylor AA, et al. J Clin Pharmacol. 1999 May;39(5):471-9. J Clin Pharmacol. 1999. PMID: 10234594

9

Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects.

Taylor AA, Shepherd AM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, Luther RR, Pool JL. Taylor AA, et al. Am J Hypertens. 1999 Sep;12(9 Pt 1):906-14. doi: 10.1016/s0895-7061(99)00068-0. Am J Hypertens. 1999. PMID: 10509549 Clinical Trial.

10

Consequences of angiotensin-converting enzyme inhibitor overdose.

Varughese A, Taylor AA, Nelson EB. Varughese A, et al. Among authors: taylor aa. Am J Hypertens. 1989 May;2(5 Pt 1):355-7. doi: 10.1093/ajh/2.5.355. Am J Hypertens. 1989. PMID: 2541742

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters